LINC01355 Suppresses Breast Cancer Growth Through FOXO3-mediated Transcriptional Repression of CCND1

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2019 Jun 28

PMID 31243265

Citations 38

Authors

Bolun Ai

Xiangyi Kong

Xiangyu Wang

Kai Zhang

Xue Yang

Jie Zhai

Ran Gao

Yihang Qi

Jing Wang

Zhongzhao Wang

Yi Fang

Affiliations

Soon will be listed here.

Abstract

Previously, several protein-coding tumor suppressors localized at 1p36 have been reported. In the present work, we focus on functional long non-coding RNAs (lncRNAs) embedded in this locus. Small interfering RNA was used to identify lncRNA candidates with growth-suppressive activities in breast cancer. The mechanism involved was also explored. LINC01355 were downregulated in breast cancer cells relative to non-malignant breast epithelial cells. Overexpression of LINC01355 significantly inhibited proliferation, colony formation, and tumorigenesis of breast cancer cells. LINC01355 arrested breast cancer cells at the G0/G1 phase by repressing CCND1. Moreover, LINC01355 interacted with and stabilized FOXO3 protein, leading to transcriptional repression of CCND1. Importantly, LINC01355-mediated suppression of breast cancer growth was reversed by knockdown of FOXO3 or overexpression of CCND1. Clinically, LINC01355 was downregulated in breast cancer specimens and correlated with more aggressive features. There was a negative correlation between LINC01355 and CCND1 expression in breast cancer samples. LINC01355 acts as a tumor suppressor in breast cancer, which is ascribed to enhancement of FOXO3-mediated transcriptional repression of CCND1. Re-expression of LINC01355 may provide a potential therapeutic strategy to block breast cancer growth and progression.

Citing Articles

POGZ targeted by LINC01355/miR-27b-3p retards thyroid cancer progression via interplaying with MAD2L2.

Lu J, Zhou X, Zhu H, Zou M, Liu L, Li X 3 Biotech. 2025; 15(4):79.

PMID: 40071126 PMC: 11890915. DOI: 10.1007/s13205-025-04231-7.

Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive review.

Afroze N, Sundaram M, Haque S, Hussain A Discov Oncol. 2025; 16(1):122.

PMID: 39912983 PMC: 11803034. DOI: 10.1007/s12672-025-01848-1.

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications.

Hu Z, Yuan L, Yang X, Yi C, Lu J Front Oncol. 2024; 14:1332528.

PMID: 38725621 PMC: 11079149. DOI: 10.3389/fonc.2024.1332528.

Long Intergenic Non-Coding RNAs of Human Chromosome 18: Focus on Cancers.

Ershov P, Yablokov E, Mezentsev Y, Ivanov A Biomedicines. 2024; 12(3).

PMID: 38540157 PMC: 10968066. DOI: 10.3390/biomedicines12030544.

Role and regulation of FOXO3a: new insights into breast cancer therapy.

Mei W, Mei B, Chang J, Liu Y, Zhou Y, Zhu N Front Pharmacol. 2024; 15:1346745.

PMID: 38505423 PMC: 10949727. DOI: 10.3389/fphar.2024.1346745.

References

Royce M, Bachelot T, Villanueva C, Ozguroglu M, Azevedo S, Cruz F . Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018; 4(7):977-984. PMC: 5885212. DOI: 10.1001/jamaoncol.2018.0060. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Karadedou C, Gomes A, Chen J, Petkovic M, Ho K, Zwolinska A . FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 2011; 31(14):1845-58. PMC: 3232453. DOI: 10.1038/onc.2011.368. View

Sisci D, Maris P, Cesario M, Anselmo W, Coroniti R, Trombino G . The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Cell Cycle. 2013; 12(21):3405-20. PMC: 3895429. DOI: 10.4161/cc.26421. View

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R . Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. Breast Cancer Res. 2014; 16(6):491. PMC: 4303201. DOI: 10.1186/s13058-014-0491-x. View

Dong Q, Yang B, Han J, Zhang M, Liu W, Zhang X . A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways. Cancer Lett. 2019; 455:60-72. DOI: 10.1016/j.canlet.2019.04.031. View

Gao J, Zhao C, Liu Q, Hou X, Li S, Xing X . Cyclin G2 suppresses Wnt/β-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1. J Exp Clin Cancer Res. 2018; 37(1):317. PMC: 6295076. DOI: 10.1186/s13046-018-0973-2. View

Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z . LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 2018; 37(47):6166-6179. DOI: 10.1038/s41388-018-0396-8. View

Zampetaki A, Albrecht A, Steinhofel K . Long Non-coding RNA Structure and Function: Is There a Link?. Front Physiol. 2018; 9:1201. PMC: 6117379. DOI: 10.3389/fphys.2018.01201. View

10.

Wang S, Ke H, Zhang H, Ma Y, Ao L, Zou L . LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018; 9(8):805. PMC: 6057987. DOI: 10.1038/s41419-018-0869-2. View

11.

Gennaro V, Stanek T, Peck A, Sun Y, Wang F, Qie S . Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proc Natl Acad Sci U S A. 2018; 115(40):E9298-E9307. PMC: 6176615. DOI: 10.1073/pnas.1807704115. View

12.

He L, Yu J, Liu L, Buyse I, Wang M, Yang Q . RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 1998; 58(19):4238-44. View

13.

Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi J . Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem. 2012; 287(21):17386-17397. PMC: 3366838. DOI: 10.1074/jbc.M111.321158. View

14.

Fernandez-Nogueira P, Noguera-Castells A, Fuster G, Recalde-Percaz L, Moragas N, Lopez-Plana A . Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer. Cancer Lett. 2018; 424:70-83. DOI: 10.1016/j.canlet.2018.03.014. View

15.

Zheng X, Zhai B, Koivunen P, Shin S, Lu G, Liu J . Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev. 2014; 28(13):1429-44. PMC: 4083087. DOI: 10.1101/gad.242131.114. View

16.

Dong H, Wang W, Mo S, Liu Q, Chen X, Chen R . Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation. J Cell Mol Med. 2018; 22(10):4935-4947. PMC: 6156344. DOI: 10.1111/jcmm.13758. View

17.

Wu X, Zhu Z, Li W, Fu X, Su D, Fu L . Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res. 2012; 14(3):R73. PMC: 3446335. DOI: 10.1186/bcr3182. View

18.

Song Y, Lu M, Qiu H, Yin J, Luo K, Zhang Z . Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells. Exp Mol Pathol. 2018; 105(1):57-62. DOI: 10.1016/j.yexmp.2018.05.013. View

19.

Liu L, Yan X, Wu D, Yang Y, Li M, Su Y . High expression of Ras-related protein 1A promotes an aggressive phenotype in colorectal cancer via PTEN/FOXO3/CCND1 pathway. J Exp Clin Cancer Res. 2018; 37(1):178. PMC: 6069867. DOI: 10.1186/s13046-018-0827-y. View

20.

Welch C, Chen Y, Stallings R . MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007; 26(34):5017-22. DOI: 10.1038/sj.onc.1210293. View